What Does the Executive Order Include?
Trump’s executive order comprises several core reforms:
- International Reference Pricing: Drug prices under Medicare will be benchmarked against those in Canada, Germany, and Australia.
- Import Expansion: The FDA will expedite pathways for importing low-cost generics and biosimilars.
- Hospital Procurement Reforms: Hospitals under federal programs must prioritize cost-effective suppliers.
- Patent Review and Reuse Policy: The administration will incentivize generic manufacturing and challenge anti-competitive patent extensions.
These changes, aimed at breaking monopolistic pricing, also signal that the U.S. is ready to embrace cheaper imports to protect domestic affordability. Source: New York Times, April 15, 2025
India’s Competitive Advantage in a New Global Pharma Order
India, known as the “pharmacy of the world,” already accounts for 20% of global generics exports by volume, according to Statista. The U.S. is its largest market, accounting for nearly 32% of India’s pharma exports in FY2024.
Here are two key insights to know about
- India vs China – FDA-Approved Facilities: India leads with over 750 U.S. FDA-approved pharma plants, compared to China’s ~120.
- India’s Pharma Export Share: The U.S. is India’s top destination for pharma exports, accounting for 32% of total shipments in FY2024.
With the U.S. government actively looking to bring down prices, Indian manufacturers offering cost savings of 30–70% over Western peers are in a strong position. Companies like Sun Pharma, Dr. Reddy’s Laboratories, Cipla, and Aurobindo are well-placed due to their robust regulatory compliance and existing U.S. FDA-approved manufacturing facilities.
| Metric | Current (2024) | Post-Order Estimate (2025-26) |
| India Pharma Exports to the U.S. | $8.2 billion | $10.5–$12 billion |
| U.S. Generic Drug Imports | $58 billion | $65–$70 billion |
| % of U.S. generics from India | 40% | >50% |
| U.S. Drug Cost Savings | — | $30 billion (Est. by 2026) |
Sources: Reuters, Economic Times, U.S. Congressional Budget Office Estimates
Winners and Losers
Winners:
- Indian Generics Manufacturers: Cost arbitrage, quality compliance, and scalability give India the edge.
- U.S. Healthcare Consumers: The executive order could cut average prescription costs by 15–20%.
- Emerging Market Drugmakers: Especially those compliant with U.S. FDA standards, like those in Brazil or Vietnam.
Losers:
- Big Pharma (U.S. and Europe): The directive threatens R&D-heavy firms that depend on pricing power in the U.S. for profitability.
- Non-compliant Foreign Suppliers: China and other low-cost regions lacking U.S. FDA approvals might struggle to meet new import standards.
Challenges for Indian Pharma: Not All Smooth Sailing
While Trump’s executive order presents a historic growth window for India’s pharmaceutical sector, several structural and economic challenges must be addressed before Indian drugmakers can fully seize the opportunity.
1. Regulatory Compliance & Inspection Risk
The U.S. Food and Drug Administration (FDA) has significantly ramped up its overseas inspection frequency, particularly for Indian plants. According to the FDA’s FY2023 inspection data, Indian pharma plants accounted for over 30% of all global warning letters. Even a minor deviation in quality control can lead to import alerts or plant bans.
Example: In early 2023, Aurobindo Pharma faced delays in product launches after the FDA flagged deficiencies at its Telangana unit. Such disruptions can translate into lost revenue and reduced credibility in the U.S. market.
2. Overdependence on China for APIs
Despite India’s strength in finished formulations, it still imports nearly 65% of its bulk drugs (APIs) from China, according to India’s Ministry of Chemicals and Fertilizers. Any disruption in India-China trade, whether geopolitical or logistical, could bottleneck the ability of Indian firms to meet increased demand from the U.S.
While the Production Linked Incentive (PLI) Scheme for APIs aims to reduce this dependence, it is still in the early execution stages and not yet impactful at scale.
3. Pricing Pressure and Margin Squeeze
Greater volume doesn’t always mean higher profitability. The U.S. generics market has become intensely competitive. The average price erosion for Indian generics in the U.S. stood at 8–10% in FY2024, according to ICRA. This price war, exacerbated by group purchasing organizations (GPOs), can severely impact profit margins even as top-line revenue grows.
4. Skilled Manpower and Capacity Constraints
Companies will need to ramp up manufacturing capacities to meet elevated global demand. But this brings logistical challenges regarding trained workforce, technology upgrades, and ensuring 24/7 operations at FDA-approved sites. Such an expansion push could strain operational resilience in an industry already at ~75% utilization.
5. Trade Policy Uncertainty
India also faces uncertainties around U.S. trade preferences. The Generalized System of Preferences (GSP), which India previously benefited from, remains suspended. Without favorable trade terms or tariff reductions, Indian exports may face cost disadvantages despite demand tailwinds.
Global Ripple Effects: A Realignment in Healthcare Economics
Trump’s pricing overhaul isn’t just a U.S. domestic policy — it sends shockwaves across the global pharmaceutical supply chain and may accelerate long-term systemic shifts.
1. The Decline of Big Pharma Pricing Power
The executive order undermines the high-margin model of the U.S. and EU-based Big Pharma, which has traditionally relied on the U.S. market to recover R&D costs. With drug markups of up to 400–800% over manufacturing cost, the forced price benchmarking could pressure revenues and pipeline investments.
According to the Congressional Budget Office, the directive could reduce branded drugmakers’ annual revenues by $45–$60 billion over five years, forcing a revaluation of R&D-heavy portfolios.
2. The China Conundrum
China has long aimed to challenge India in the generics space, but lacks equivalent FDA penetration. As of 2024, India held 750+ U.S. FDA-approved facilities, compared to under 120 for China. The U.S.’s current geopolitical posture makes it unlikely to prefer deeper Chinese dependence in critical health sectors.
However, China’s dominant position in APIs still gives it bargaining power. Any retaliatory move in bulk drug exports could affect multiple nations, including the U.S., creating a policy paradox: push India for finished drugs, but rely on China for ingredients.
3. Opportunity for Secondary Players
Countries like Vietnam, Bangladesh, and Mexico, with lower-cost labor and improving regulatory ecosystems, may emerge as alternative suppliers, especially for less complex generics. Given its proximity to the U.S., Mexico may benefit from USMCA trade benefits and logistics efficiency.
Still, India’s established compliance and scale will likely remain the top beneficiary, at least in the short to medium term.
4. EU and Japan May Follow the U.S. Lead
Analysts from McKinsey and Brookings suggest that the U.S. move could pressure other developed markets to reevaluate their drug pricing and procurement models. Germany and France have already hinted at examining their hospital procurement supply chains post-COVID-19 disruptions. If it can diversify export destinations, India could gain across multiple continents.
A Defining Opportunity for India’s Pharma Sector
Though controversial domestically, Trump’s drug pricing directive provides a strong external tailwind to India’s pharmaceutical exports. With the right mix of regulatory compliance, production scaling, and strategic alliances, India could significantly increase its global pharma share in the coming years.
However, to fully capitalize, Indian companies must double down on:
- FDA-compliant manufacturing.
- Diversifying API supply chains.
- Investing in biosimilars and specialty generics.
This could be a defining moment, not just for profits, but for India’s global positioning in healthcare economics.
Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This article is for education purposes only and shall not be considered as a recommendation or investment advice by Equentis – Research & Ranking. We will not be liable for any losses that may occur. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL & the certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors.
